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Summary Previously we reported that fusogenic liposomes, prepared by fusing simple liposomes with Sendai
virus particles, could introduce their contents directly and efficiently into the cytoplasm. In this study, we
examined the anti-tumour activity of fusogenic liposomes containing fragment A of diphtheria toxin (DTA).
Fusogenic liposomes containing DTA showed high cytotoxicity against sarcoma-180 (S-180) cells in vitro.
When these liposomes were administered into the abdominal cavity of ddY mice carrying S-180, tumour cells
completely disappeared in four of six tumour-bearing mice without decrease in body weight. Neither simple
liposomes containing DTA nor empty fusogenic liposomes had any effect on tumour suppression. We conclude
that fusogenic liposomes containing DTA are new and potentially effective tools for the treatment of ascites
tumours without any severe side-effects.
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Various inhibitors of cell metabolism have been used as anti-
cancer drugs. However, these agents also have profound
effects on normal cells, leading to severe side-effects.
Liposomes have been used as slow-releasing capsules to
alter the plasma clearance and tissue distribution of anti-
cancer drugs. Liposomes can also be used to target cancer
cells by attachment of an antibody against the surface
molecules of these cells. The anti-cancer activities of these
liposomes are, however, not sufficiently high for practical
cancer therapy (Wright and Huang., 1989), perhaps owing to
the degradation of most drugs by lysosomal enzymes after
the liposomes are taken up by endocytosis (Wright and
Huang., 1989; Casellas et al., 1988; Colombatti et al., 1990).
Protein toxins are another type of candidate molecule that
has potential anti-cancer activity (Wawrzynczak, 1991).
Immunotoxins, prepared by conjugation of subunits of
various protein toxins with anti-tumour antibodies, show
cytotoxicity to target cells in vitro. However, the therapeutic
efficacy of immunotoxins is currently limited by the relatively
weak action of immunotoxins in vivo. One of the reasons is
that most immunotoxins are degraded by lysosomal enzymes
after cells take them up by endocytosis (Wawrzynczak, 1991).
To overcome this inefficiency a system that allows these
molecules to penetrate directly into cells is required.
Previously we reported the preparation and characterisa-
tion of fusogenic liposomes, which have virus envelope
proteins on their surface (Uchida et al., 1979; Nakanishi et
al., 1985; Kato et al., 1991a,b; Nakanishi and Okada, 1993;
Nakanishi et al., 1995; M Nakanishi et al, manuscript in
preparation). The fusogenic liposome fuses with the cell
membrane in a receptor-dependent manner similiar to the
native virus particle. This system is unique in comparison
with other drug delivery systems, because the fusogenic
liposomes can deliver their contents directly into the
cytoplasm. Using these liposomes, we have delivered, intact
macromolecules such as proteins and DNA into tissue cells as
well as cultured cells (Uchida et al., 1979; Nakanishi et al.,
1985; Kato et al., 1991a,b; Nakanishi and Okada, 1993;
Nakanishi et al., 1995; M Nakanishi et al., manuscript in
preparation).
We also found that fusogenic liposomes containing
fragment A of diphtheria toxin (DTA) killed cultured cells
quite efficiently (Uchida et al., 1979; Nakanishi et al., 1985;
Nakanishi et al., 1995; M Nakanishi et al., manuscript in
preparation). DTA is known to kill cells by inactivating
elongation factor 2 even when only one molecule of this
protein is introduced into the cytoplasm, whereas it is
absolutely non-toxic even if it is taken up by endocytosis,
because it cannot reach the cytoplasm owing to degradation
by lysosomal enzymes (Yamaizumi et al., 1978; Uchida,
1982).
In this paper, we report that administration of unilamellar
fusogenic liposomes containing DTA resulted in complete
remission in mice carrying sarcoma-180 (S-180) cells without
producing any side-effects.
Materials and methods
Materials
Egg phosphatidylcholine (PC) and L-a-dimyristoryl phospha-
tidic acid (PA) were obtained from Nippon Oil & Fats,
Tokyo, Japan. Cholesterol (Chol) was obtained from Sigma,
St Louis, MO, USA. Polycarbonate membrane (pore size
0.2 jim. Nuclepore) was obtained from Costar, Cambridge,
MA, USA. Male ddY mice were obtained from Shimizu
Experimental Animal Co, Kyoto, Japan. DTA was prepared
as described previously (Uchida et al., 1979) with modifica-
tion using hydophobic chomatography and ion exchange
chromatography (M Nakanishi et al., manuscript in
preparation). Cytotoxicity of DTA was examined by using
toxin-sensitive Vero cells. We found that DTA prepared by
us was not toxic to the cells even when it was added in
cultured medium at 100 jig ml-' for 24 h (M Nakanishi et
al., manuscript in preparation).
Cells and virus
S-180 cells were maintained by i.p. passage in ddY mice.
Human HeLa cells were cultured with Eagle's minimum
essential medium (MEM) supplemented with 10% fetal calf
serum (FCS). Primary human peripheral lymphocytes were
prepared using Mono-Poly Resolving Medium (Dainippon
Pharmaceutical, Osaka, Japan) and cultured with RPMI-1640
medium supplemented with 10% FCS, 50 jiM 2-mercap-
toethanol and 5 jig ml-' Phaseolus vulgaris Agglutinin-P
Sendai virus (Z strain) was prepared as described previously
(Nakanishi et al., 1985).
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Preparation and characterisation offusogenic liposomes
containing DTA
Unilamellar liposomes were prepared by a reverse-phase
evaporation method (Szoka and Papahadjopoulos., 1978)
with some modifications (Nakanishi et al., 1995) using 200 ,ug
of purified DTA and 46 Mmol of lipids (PC/PA/Chol= 5: 1: 4
molar ratio). After preparation, the liposomes were sized by
extrusion through a 0.2,m polycarbonate membrane and
were then separated from unencapsulated DTA by sucrose
step centrifugation. The liposomes prepared as described
above have average diameter of 300 nm (Nakanishi et al.,
1995). Under these conditions, about 200 molecules of DTA
were encapsulated in a liposome particle.
Unilamellar fusogenic liposomes were prepared as
described elsewhere (Nakanishi et al., 1995; M Nakanishi et
al., manuscript in preparation). Briefly, liposomes were mixed
with Sendai virus and incubated at 37°C for 2 h with
shaking. Fusogenic liposomes were separated from free
liposomes and Sendia virus by sucrose step centrifugation
(24 000 r.p.m., 2 h). The fusogenic liposomes prepared as
described above have average diameter of 380 nm (Nakanishi
et al., 1995). For inactivation of the genomic RNA of Sendai
virus purified fusogenic liposomes were treated with ultra-
violet irradiation (2 000 J m-2) just before use.
The amount of DTA encapsulated within liposomes was
determined by measuring NAD-elongation factor 2 (EF2)-
ADP-ribosyl transferase (ADPR) activity (Carroll and
Collier., 1988) after lysis by Triton X-100, using EF2 partially
purified from rabbit liver (Takamatsu et al., 1986). Liposome
and fusogenic liposome suspensions at the optical density of
1.0 at 540 nm (OD540= 1.0) contained 3.61 and 0.52 Mg DTA
ml-' respectively . Before lysis with detergent, these samples
showed no NAD/EF/2/ADPR activity, indicating that most of
the DTA was present inside the liposomes.
Protein was determined by a Bio-Rad protein assay kit
using bovine serum albumin as a standard. Lipid was
measured with the Phospholipids B-Test Wako (Wako,
Osaka, Japan). The haemagglutinating activity was deter-
mined as described previously (Kato et al., 1991a). Fusogenic
liposome suspension with OD540 of 1.0 contained 0.78 mg
protein ml-1 and 0.95 Mmol lipid ml-', and showed 15 000
haemagglutinating units (HAUs) ml-'.
Cytotoxic activity in vitro
To determine the cytotoxicity of fusogenic liposomes
containing DTA, 1 x 106 S-180 cells and primary human
lymphocytes or 5 x 104 HeLa cells seeded on 24-wells were
incubated with 50 Ml or 200 Ml of fusogenic liposomes
containing DTA at 37°C for 30 min, respectively. After
20 h in culture, the cells were pulse-labelled with [35S]-
methionine (20 MCi ml-', I h) and [35S]count incorporated
into TCA-precipitable materials was determined.
Assay for anti-tumour activity in vivo
S-180 cells (1 x 106) were injected i.p. into male ddY mice (5
weeks, 23-26 g) on day 0. After 24 h, liposomes suspended
in 250 Ml of buffered salt solution (BSS) (10 mM Tris-HCl,
150 mm sodium chloride, pH 7.6) was given i.p. The body
weight was measured every 2 or 3 days, and the mortality
was monitored. Complete regression was defined as mouse
survival or more than 60 days.
To examine the direct cytotoxicity of fusogenic liposomes
containing DTA against S-180 cells in vivo, S-180 cells in
ascites were collected and the number of live cells was
counted at 2 days after i.p. injection of the liposomes.
Measurement of the amount of DTA delivered into S-180
cells
For in vitro experiment, 1 x 106 S-180 cells were treated with
fusogenic liposomes containing DTA with OD540 of 0.1 as
described above. After 30 min, the cells were washed three
times with ice-cold BSS and the cell-associated NAD/EF2/
ADPR activity was determined using the Nonidet P-40-
treated cell extract as described previously (Takamatsu et al.,
1986).
For in vivo experiment, fusogenic liposomes containing
DTA with OD5Q of 1.0 were injected i.p. as described above.
After 30 min, S-180 cells in ascites were collected and the cell-
associated NAD/EF2/ADPR activity was determined as
above.
Results
In vitro cytotoxicity offusogenic liposomes
Previously we reported that our fusogenic liposomes fused
with cell membrane using the mechanism of infection by
Sendai virus, and that fusogenic liposomes containing DTA
killed mouse L cells and human HeLa cells quite efficiently
(Uchida et al., 1979; Nakanishi et al., 1985, 1995, M
Nakanishi et al., manuscript in preparation). Because Sendai
virus can infect a wide variety of cells with sialic acid, a
common component of glycolipid and glycoprotein, as
receptors, the fusogenic liposomes containing DTA may kill
a variety of cells, including tumorigenic cells or suspension
cells. However, as fusogenic liposomes containing DTA could
not kill primary human lymphocytes even at high concentra-
tion (Figure 1), these liposomes could not fuse with all kinds
of cells.
We examined whether the liposomes containing DTA
could kill tumorigenic S-180 cells in suspension in vtiro
(Figure 1). Fusogenic liposomes containing DTA killed S-180
cells in a dose-dependent manner, and 50 ,u1 of the liposomes
with OD540 of 0.1 killed 1 x 106 S-180 cells. Neither simple
liposomes containing DTA nor empty fusogenic liposomes
had any influence on the viability of S-180 cells (Figure 1).
These results suggested that fusogenic liposomes containing
DTA could kill S-180 cells efficiently in vitro by introducing
DTA into the cytoplasm.
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Figure 1 In vitro cytotoxicity of fusogenic liposomes containing
DTA against S-180, HeLa cells and primary human lymphocytes.
S-180 cells (1 x 106) and primary human lymphocytes or 5 x 104
HeLa cells seeded on 24 wells were incubated with 50 ,ul or 200 pl
of fusogenic liposomes containing DTA at 37°C for 30min,
respectively. After 20h in culture the cells were pulse-labelled with
[35S]-methionine (20 pCi ml-1, 1 h) and the 35S incorporated into
TCA-precipitable materials was determined. 0, S-180 cells
treated with fusogenic liposome containing DTA; 0, HeLa cells
treated with fusogenic liposome containing DTA; C], primary
human lymphocytes treated with fusogenic liposome containing
DTA; *, S-180 cells treated with simple liposome containing
DTA; A, S-180 cells treated with empty fusogenic liposome. Data
are expressed as average of two or three experiments.
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In vivo anti-tumour activity offusogenic liposomes
Next we examined whether we could apply this in vitro
phenomenon to in vivo cancer therapy. At 24 h after i.p.
inoculation of S-180 cells (1 x 106) into mice, 250 pl of
liposome suspension was injected i.p. When fusogenic
liposomes containing DTA with OD540 of 1.0 were injected,
S-180 cells in ascites completely disappeared 2 days after the
administration of the liposomes (Table I). These results
showed that fusogenic liposomes also fused with S-180 cells
in the abdominal cavity of the mice. We also examined the
survival of the mice given various kinds of liposomes (Figure
2 and Table II). Prolonged survival was observed in mice
treated with fusogenic liposomes containing DTA. The rate
of survival increased with the amount ofliposomes. Complete
regression was observed in 67% and 50% of the mice given
250 M1 of fusogenic liposomes containing DTA with OD540 of
1.0 and 0.5 respectively. Mice with complete regression were
tumour-free even at 90 days after tumour inoculation.
In contrast, treatment of mice with simple liposomes
containing DTA or with empty fusogenic liposomes cannot
suppress tumour growth (Figure 2 and Table II), and the
number of S-180 cells in ascites was almost the same as
control (Table I). Furthermore, treatment of the tumour-
bearing mice with purified DTA (10 pg per mouse) had no
effect on tumour suppression (data not shown). The results in
vitro and in vivo showed that S-180 cells were killed by direct
introduction of DTA through fusion with fusogenic
liposomes. We performed two additional animal experiments
with fusogenic liposomes and obtained almost similar results.
Moreover, we found that i.p. injection of fusogenic liposomes
containing DTA cured 67% of the mice even when these
liposomes were administered 4 days after S-180 cells were
inoculated (data not shown), suggesting that the treatment of
fusogenic liposomes is effective at a more advanced stage of
cancer.
To compare the efficiency of the fusogenic liposomes in
delivering DTA to S-180 cells in vitro and in vivo, we
determined the amount of DTA associated with S-180 cells
(Table III). In in vitro experiments, the amount of DTA
delivered into 1 x 106 S-180 cells (0.64 ng) was 25% of that
inoculated with fusogenic liposomes (2.6 ng). In in vivo
experiments, the amount of DTA delivered (0.52 ng) was
0.4% of that inoculated with fusogenic liposomes (130 ng).
These data showed that the fusogenic liposomes fused with S-
180 cells 60 times less efficiently in vivo than in vitro, and that
about 0.5 ng of DTA was sufficient to kill 1 x 106 S-180 cells
both in vitro and in vivo if delivered by the fusogenic
liposomes. This was in great contrast to the result that 10 jug
of pure DTA alone had no effect on growth of S-180 cells in
vivo (see above).
Side-effects caused by administration offusogenic liposomes
We also examined whether fusogenic liposomes containing
DTA affected other functions of living mice when injected i.p.
Figure 3 shows the course of mean body weight change ofthe
mice injected with various kinds of liposomes. Compared
with control mice injected with neither S-180 cells nor
fusogenic liposomes, none of the mice injected with S-180
cells and fusogenic liposomes containing DTA showed any
decrease in body weight, except those injected at the highest
concentration, which showed 97% of the control body
weight. The body weight of the mice administered these
liposomes with OD540 of 0.25 and 0.1 was similar to that of
those administered liposomes with OD540 of 0.5 (data not
shown). In contrast, the mean body weights of the groups
injected with BSS, simple liposomes containing DTA or
empty fusogenic liposomes showed a greater increase as a
result of the growth of the tumour cells.
The mice injected i.p. with fusogenic liposomes containing
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Table I Number of S-180 cells in ascites after the administration of
fusogenic liposomes containing DTA
Dose Cell number
Treatment (OD540) ( x 106 cells)
BSS - 14.0± 3.8
Liposome containing DTA 1.0 17.7±2.1
Empty fusogenic liposome 1.0 14.8 ± 5.2
Fusogenic liposome containing DTA 1.0 <0.06
ddY Mice were inoculated i.p. with 1 x 106 S-180 cells and injected
with each material on day 1. After 2 days S-180 cells in ascites were
collected and the number of live cells was measured. Means ± s.d.
Figure 2 Survival of ddY mice inoculated with S-180 cells and
injected with fusogenic liposomes containing DTA. ddY mice
were inoculated i.p. with 1 x 106 S-180 cells. After 24h, the mice
were treated with a single i.p. injection of 250 1l of BSS,
liposomes containing DTA with OD540 of 1.0, empty fusogenic
liposomes with OD540 of 1.0, or fusogenic liposomes containing
DTA with OD540 of 1.0, 0.5, 0.25 or 0.1. 0, BSS; *, liposome
containing DTA (OD540=1.0); El, empty fusogenic liposome
(OD540 = 1.0); *, fusogenic liposome containing DTA (OD540 =
1.0); A, fusogenic liposome containing DTA (OD540=0.5); A,
fusogenic liposome containing DTA (OD540 =0.25); x, fusogenic
liposome containing DTA (OD540=0.1).
Table II Anti-tumour effect of fusogenic liposomes containing DTA on S-180 cells transplanted i.p. into ddY mice
Treatment Dosea (OD540) Survivalperiodb (days) T/CC (%) Complete regressiond
BSS - 12.8 ±1.9e 100.0 0/6
Liposome containing DTA 1.0 15.0+ 1.8 116.9 0/6
Empty fusogenic liposome 1.0 14.8+2.3 115.6 0/6
Fusogenic liposome 1.0 > 52.0 >405.3 4/6
containing DTA 0.5 >48.5 >378.0 3/6
0.25 38.1 ±4.0 297.5 0/6
0.1 22.3+ 3.8 174.1 0/6
ddY Mice were inoculated i.p. with 1 x 106 S-180 cells and injected with each material on day 1. aAdministration of250 ,u
per mouse. bDays after tumour inoculation. cSurvival period (days) of sample/survival period (days) of controlx 100.
Complete regression was defined as survival period exceeding 60 days. All surviving mice shown in this table were free from
tumour even at day 90. eMeans± s.e. T/C, tumour-control ratio.
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Table III Amount of DTA delivered into S-180 cells by fusogenic
liposome
DTA content delivered into S-180 cells
(ng DTA I x106 cells)
In vitro 0.64
In vivo 0.52
Fusogenic liposomes containing DTA (50 pl) with OD540 of 0.1
were treated with 1 x 106 S-180 cells in vitro. For in vivo experiments,
the mice were inoculated i.p. with 1 x 106 S-180 cells, and next day
250 MI offusogenic liposomes containing DTA with OD540 of 1.0 was
injected i.p. After 30 min the amount of DTA in S-180 cells was
determined by measuring NAD/EF2/ADPR activity. Data were the
average oftwo independent experiments.
90
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Figure 3 Body weight change of the mice inoculated with
fusogenic liposomes containing DTA. Body weight was measured
at intervals of 2 or 3 days after sample administration. +, Non-
treatment; 0, BSS; 0, liposome containing DTA (OD540 = 1.0);
C], empty fusogenic liposome (OD540= 1.0); *, fusogenic
liposome containing DTA (OD540= 1.0); A, fusogenic liposome
containing DTA (OD540=0.5). Each data point represents mean
+s.e. for six mice.
DTA showed no other side-effects by appearance. These
results demonstrated that fusogenic liposomes containing
DTA killed S-180 cells efficiently without inducing any severe
side-effects.
Comparison with other anti-tumour drugs
We also examined the effect of mitomycin C (MMC), an
antibiotic with anti-tumour activity against various kinds of
tumours (Crooke, 1979), on S-180 ascitic tumours. The i.p.
administration of MMC at the dose of 2.5 and 5.0 mg kg-'
of body weight resulted in tumour-suppressive effects similar
to those of fusogenic liposomes containing DTA with OD,40
of 0.5 and 1.0 (data not shown). However, the body weight
was decreased by over 5% on the day following the injection
of MMC (data not shown). Furthermore, the loss of hair,
sores of the skin on the abdomen and the loss of whiskers
were observed in all mice. The degree of these side-effects was
in striking contrast to the absence of side-effects caused by
fusogenic liposomes.
Discussion
Fragment A of diphtheria toxin (DTA), the N-terminal
peptide of the toxin with a molecular weight of 22 000, is
absolutely non-toxic when it is located outside the cell
membrane because it cannot enter the cytoplasm. However, if
even one molecule of this peptide enters the cytoplasm, it can
kill the cell (Yamaizumi et al., 1978; Uchida, 1982).
Therefore, DTA is a highly potent molecule for cancer
therapy, provided that it can be delivered specifically into the
tumour cells. We found that the fusogenic liposomes satisfied
this requirement and that strong tumour-suppressive effects
were obtained upon treatment of S-180 cells with fusogenic
liposomes containing DTA in vitro and in vivo. To kill 1 x
106 S-180 cells in vitro and in vivo, 0.6 ng of DTA was
sufficient.
In contrast to fusogenic liposomes containing DTA, simple
liposomes containing DTA, empty fusogenic liposomes and
purified DTA could not suppress tumour growth. These
results showed that direct introduction of DTA into the
cytoplasm of tumour cells was essential for tumour
suppression and excluded the possibility that the immuno-
genic reaction against Sendai virus or the release ofcytokines,
which may be induced by the administration of fusogenic
liposomes, participated in tumour suppression.
Surprisingly, the administration of fusogenic liposomes
containing DTA did not result in any severe side-effects or
altered appearance, even though the fusogenic liposomes
have the capacity to deliver their contents into a variety of
cells. The abdominal side of the stomach, liver, intestine,
kidney and spleen were histologically normal (data not
shown). One of the possible explanations for this selective
toxicity to tumour cells is that the extracellular matrix of
these organs might prevent the fusion of fusogenic liposomes
with the cell membrane, but the detailed mechanism of this
apparent specificity remains as a future problem.
There are other characteristics that may contribute to low
non-specific toxicity to the body. The average diameter of the
injected fusogenic liposomes containing DTA was 380 nm
(Nakanishi et al., 1995), and therefore they would not
circulate through the whole body. Furthermore, DTA is
non-toxic even when it is released from fusogenic liposomes.
Administration of 10 ug of DTA (alone) did not show any
effects in the mice (data not shown). These characteristics
contrast with those of other low molecular weight anti-cancer
drugs, and also may contribute to the absence of side-effects.
Although various methods have been developed to
introduce foreign genetic materials into cells, only a few
techniques have been developed to deliver proteins into the
cytoplasm. The fusogenic liposomes in our system can deliver
various kinds of proteins directly and efficiently into the
cytoplasm because they fuse with the cell membrane through
the mechanism of Sendai virus infection (Nakanishi et al.,
1985). The efficiency of fusogenic liposomes in introducing
their contents into the cells is the same as that of infection
with intact Sendai virus (Nakanishi et al., 1995). Huang et al.
reported that pH-sensitive immunoliposomes can deliver
encapsulated DTA into the cytoplasm (Wang and Huang,
1989; Collins et al., 1990; Litzinger and Huang, 1992; Tari et
al., 1994). However, these pH-sensitive immunoliposomes
showed protein synthesis inhibition of only 50-70% at
maximum, and could not kill all the cells (Collins et al., 1990;
Tari et al., 1990). Judging from the concentration of DTA
required to kill the cells, our system is far more efficient. This
superior efficiency in protein delivery is another important
aspect of possible cancer therapy using DTA.
The results described herein are a first attempt to examine
the potential activity of fusogenic liposomes in cancer
therapy. Fusogenic liposomes containing DTA may be a
potential new therapeutic approach in the treatment of ascitic
tumours and may also be effective in the local treatment of
solid tumours and the treatment of malignant pleural
effusion.
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